This 2-sided 3.5"x2" business-sized wallet card helps publicize the 988 Suicide & Crisis Lifeline.

This 2-sided 3.5"x2" business-sized wallet card helps publicize the 988 Suicide & Crisis Lifeline.

SAMHSA expects print materials to be available for ordering in late July. We will regularly update the SAMHSA Store links when products arrive. This cellphone-shaped magnet (size 3.25"x6") helps publicize the new 988 Suicide & Crisis Lifeline phone number and provides access to this life-saving resource in places that are highly visible.

SAMHSA expects print materials to be available for ordering in late July. We will regularly update the SAMHSA Store links when products arrive. This 4.75" by 4.75"-sized magnet helps publicize the new 988 Suicide & Crisis Lifeline phone number and provides access to this life-saving resource in places that are highly visible.

This 18x24 inch poster helps publicize the new 988 Suicide & Crisis Lifeline and provides access to this life-saving resource. This poster is designed to be placed in community centers, counseling offices, clinics, and other settings where people gather.

This 18x24 inch poster helps publicize the new 988 Suicide & Crisis Lifeline and provides access to this life-saving resource. This poster is designed to be placed in schools, community centers, counseling offices, clinics, and other settings where people gather.

SAMHSA expects print materials to be available for ordering in late July. We will regularly update the SAMHSA Store links when products arrive. The Safety Plan is a 5”x7” pad, similar to a prescription pad, with 50 sheets of pulloff plans. The intended use is for counselors, therapists, clinicians, and others working with people in need of safety plans. It is modified from Stanley & Brown.

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.